Latest Breaking News On - ஹ்ஸீ வேந்‌ரைட் உலகளாவிய வாழ்க்கை அறிவியல் மாநாடு - Page 1 : comparemela.com

Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2021. “Bellerophon remains focused on advancing its INOpulse® inhaled nitric oxide therapy in multiple high-value areas of unmet need as expeditiously as possible,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. “Enrollment in our ongoing pivotal Phase 3 REBUILD study for fibrotic interstitial lung disease, or fILD, patients at risk of associated pulmonary hypertension continues to advance. We also anticipate top-line results from our Phase 2 dose escalation study of INOpulse in sarcoidosis, or PH-Sarc, later this year. Our

United statesSan diegoFabian tenenbaumBrian ritchieExchange commissionUniversity of californiaHc wainwright global life sciences conferenceBellerophon therapeutics incClinical programBellerophon therapeuticsChief executive officerProgram highlightsSan diego shortnessBreath questionnaireGlobal life sciencesQuarter ended march